To evaluate therapies available for the treatment of irritable bowel syndrome, and provide
consensus recommendations for their use, a total of 51 double‐blind clinical trials using …

This review summarizes the clinical evidence to support current therapies in irritable bowel
syndrome (IBS). Fibre is indicated at a dose of at least 12 g per day in patients with …

Background Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder.
The role of pharmacotherapy for IBS is limited and focused mainly on symptom control …

Background Although novel therapies for irritable bowel syndrome (IBS) continue to be
developed, many doctors rely on more established, traditional therapies as first-line or …

In order to identify relevant IBS therapy trials for inclusion in this guideline, the following
literature search techniques were employed. Separate PUBMED, MEDLINE, and EMBASE …

The irritable bowel syndrome (IBS) remains a therapeutic challenge in part because of the
limited understanding of the pathophysiology. The placebo response rate varies in …

Background Numerous meta-analyses have recently assessed the overall clinical benefit of
single therapy options and groups of therapies in the irritable bowel syndrome (IBS). By …

Aim To use an evidence‐based approach to evaluate the safety and tolerability of the
treatments available for irritable bowel syndrome (IBS), or in clinical development, in …

Background Irritable bowel syndrome (IBS) is a common health problem, often presenting in
primary care as well as in internal medicine and gastroenterology outpatient clinics …

Objective To determine the effect of fibre, antispasmodics, and peppermint oil in the
treatment of irritable bowel syndrome. Design Systematic review and meta-analysis of …